Reference-grade research compound
Retatrutide
LY-3437943, GLP-1 / GIP / glucagon triple receptor agonist (research grade)
Schematic — no PDB structure deposited
- Scientific name
- LY-3437943, GLP-1 / GIP / glucagon triple receptor agonist (research grade)
- Sequence
- —
- Length
- 39-mer
- Molecular formula
- C221H343N53O67
- Molecular weight
- 4731.36 g/mol
- Form
- lyophilized
- Available sizes
- 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg
- Storage
- Store lyophilized powder at −20 °C, desiccated and protected from light. Stable for 24 months.
- Batch HPLC purity
- 99.3%
Description
39-residue synthetic peptide developed as a triple agonist at GLP-1, GIP, and glucagon receptors. Used in vitro as a reference compound in receptor-binding and downstream cAMP / β-arrestin assays at heterologously expressed GLP-1R, GIPR, and GCGR. Supplied as a lyophilized acetate salt.
Storage and stability
Store lyophilized powder at −20 °C, desiccated and protected from light. Stable for 24 months.
Peer-reviewed references
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.
Front Endocrinol (Lausanne) · 2024
PMID 39114288PubMedTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
N Engl J Med · 2023
PMID 37366315PubMedRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Lancet · 2023
PMID 37385280PubMed
Titles and journals pulled from PubMed and cached for 7 days. Links open in a new tab.